Literature DB >> 23887589

Frequency of TERT promoter mutations in human cancers.

João Vinagre1, Ana Almeida, Helena Pópulo, Rui Batista, Joana Lyra, Vasco Pinto, Ricardo Coelho, Ricardo Celestino, Hugo Prazeres, Luis Lima, Miguel Melo, Adriana Gaspar da Rocha, Ana Preto, Patrícia Castro, Ligia Castro, Fernando Pardal, José Manuel Lopes, Lúcio Lara Santos, Rui Manuel Reis, José Cameselle-Teijeiro, Manuel Sobrinho-Simões, Jorge Lima, Valdemar Máximo, Paula Soares.   

Abstract

Reactivation of telomerase has been implicated in human tumorigenesis, but the underlying mechanisms remain poorly understood. Here we report the presence of recurrent somatic mutations in the TERT promoter in cancers of the central nervous system (43%), bladder (59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers, the presence of TERT promoter mutations (when occurring together with BRAF mutations) is significantly associated with higher TERT mRNA expression, and in glioblastoma we find a trend for increased telomerase expression in cases harbouring TERT promoter mutations. Both in thyroid cancers and glioblastoma, TERT promoter mutations are significantly associated with older age of the patients. Our results show that TERT promoter mutations are relatively frequent in specific types of human cancers, where they lead to enhanced expression of telomerase.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23887589     DOI: 10.1038/ncomms3185

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  344 in total

1.  Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis.

Authors:  Jiang-Jiang Qin; Wei Wang; Sushanta Sarkar; Ruiwen Zhang
Journal:  J Control Release       Date:  2016-07-06       Impact factor: 9.776

2.  Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.

Authors:  Sumit Borah; Linghe Xi; Arthur J Zaug; Natasha M Powell; Garrett M Dancik; Scott B Cohen; James C Costello; Dan Theodorescu; Thomas R Cech
Journal:  Science       Date:  2015-02-05       Impact factor: 47.728

3.  Expression of the human telomerase reverse transcriptase gene is modulated by quadruplex formation in its first exon due to DNA methylation.

Authors:  Pei-Tzu Li; Zi-Fu Wang; I-Te Chu; Yen-Min Kuan; Ming-Hao Li; Mu-Ching Huang; Pei-Chi Chiang; Ta-Chau Chang; Chin-Tin Chen
Journal:  J Biol Chem       Date:  2017-10-30       Impact factor: 5.157

4.  Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.

Authors:  Nancy E Thomas; Sharon N Edmiston; Yihsuan S Tsai; Joel S Parker; Paul B Googe; Klaus J Busam; Glynis A Scott; Daniel C Zedek; Eloise A Parrish; Honglin Hao; Nathaniel A Slater; Michelle V Pearlstein; Jill S Frank; Pei Fen Kuan; David W Ollila; Kathleen Conway
Journal:  Am J Dermatopathol       Date:  2019-04       Impact factor: 1.533

5.  Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations.

Authors:  Lindley Maryoung; Yangbo Yue; Ashley Young; Chad A Newton; Cindy Barba; Nicolai S C van Oers; Richard C Wang; Christine Kim Garcia
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

6.  Molecular profiling of clear cell adenocarcinoma of the urinary tract.

Authors:  Chieh-Yu Lin; Atif Saleem; Henning Stehr; James L Zehnder; Benjamin A Pinsky; Christian A Kunder
Journal:  Virchows Arch       Date:  2019-08-02       Impact factor: 4.064

7.  High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.

Authors:  Doreen Nguyen; Diana Taheri; Simeon Springer; Morgan Cowan; Gunes Guner; Maria Angelica Mendoza Rodriguez; Yuxuan Wang; Isaac Kinde; Christopher J VandenBussche; Matthew T Olson; Bernardo F P Ricardo; Isabela Cunha; Kazutoshi Fujita; Dilek Ertoy; Kenneth W Kinzler; Trinity J Bivalacqua; Nickolas Papadopoulos; Bert Vogelstein; George J Netto
Journal:  Virchows Arch       Date:  2016-08-12       Impact factor: 4.064

8.  Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.

Authors:  Semen Onder; Sule Ozturk Sari; Gulcin Yegen; Ismail Cem Sormaz; Ismail Yilmaz; Sukran Poyrazoglu; Yasemin Sanlı; Yasemin Giles Senyurek; Yersu Kapran; Ozgur Mete
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

9.  Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.

Authors:  Yohan Suryo Rahmanto; Jin-Gyoung Jung; Ren-Chin Wu; Yusuke Kobayashi; Christopher M Heaphy; Alan K Meeker; Tian-Li Wang; Ie-Ming Shih
Journal:  J Biol Chem       Date:  2016-03-07       Impact factor: 5.157

Review 10.  Biologic and Clinical Perspectives on Thyroid Cancer.

Authors:  James A Fagin; Samuel A Wells
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.